Catalyst Science Discovery Centre appoints director
Widnes, Cheshire-based firm welcomes Stephen Youd-Thomas
Stephen Youd-Thomas runs a successful corporate and social responsibility consultancy and was formerly head of social goals at the Co-operative Group.
‘This is a wonderful opportunity to help develop the work of the UK's only science discovery centre with chemistry as its main theme. Catalyst brings chemistry alive for thousands of young people from across the North West and beyond and hopefully this experience will encourage many of them to consider a career in science in the future,’ he said.
Catalyst is an independent charitable trust operated by Catalyst Science Discovery Centre and Museum Trust.
You may also like
Research & Development
![Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal]()
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
![FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance]()
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance
The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Hi Tech Manufacturing
![Gerresheimer significantly accelerates mould development in medical technology with “Digital Mold”]()
Gerresheimer significantly accelerates mould development in medical technology with “Digital Mold”
Linking the digital twin of the mould with production data. Virtual mould and process optimisation prior to physical construction
Mould Lifecycle Management as the foundation for data analytics and AI applications in mould development and production